Drug intelligence / Profile preview

VB-892

Development stage: Preclinical
Lead developer: Variant Bio
Modality: Small Molecules

Overview

VB-892 is a small molecule drug candidate currently in the preclinical/discovery phase for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Developed by Variant Bio, the compound was identified using the company's proprietary genomic platform, which analyzes genetic data from diverse human populations to find genes associated with health and disease. While the specific molecular target of VB-892 is currently confidential, the program aims to provide a novel therapeutic approach for the progressive scarring of lung tissue characteristic of IPF.

Beyond the preview

Go deeper on VB-892.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-892.

Explore the full profile